SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Cloud FLEX
Cloud FLEX Spółka z Ograniczoną Odpowiedzialnością w Likwidacji
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Cloud FLEX Spółka z Ograniczoną Odpowiedzialnością w Likwidacji
Cloud FLEX Spółka z Ograniczoną Odpowiedzialnością w Likwidacji (KRS 0000495396, NIP 5252574269) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. CLOUD FLEX SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ W LIKWIDACJI operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since January 23, 2014.
Entity dissolved
The data shown reflects the last known state before removal.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Archived data - last known state
Status as of the last registry entry
Founded
January 23, 2014
12 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
1.0 M PLN
20,200 shares total
Shareholders
1
shareholder
Board
N/A
Filed years
N/A
Registry entries
6
latest: November 29, 2016
Risk signals
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Cloud FLEX.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Latest reporting year
2015
Available years
2
Filing entries
0
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Yes - CLOUD FLEX SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ W LIKWIDACJI's majority owner is CLOUD TECHNOLOGIES SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ.
6 historical registry entries for Cloud FLEX
Identifier change
WA.XII NS-REJ.KRS/9477/14/110
Financial statement filed, Approval of the financial statement, Change in Section 3 (business activity and filings), First fiscal year recorded
WA.XII NS-REJ.KRS/58526/15/172
Registered office change, Address change
WA.XIII NS-REJ.KRS/66097/15/180
Financial statement filed, Approval of the financial statement, Change in Section 3 (business activity and filings)
WA.XIII NS-REJ.KRS/61052/16/539
Company name change, Address change, Governance body name change, Representation rule change, Dissolution, Board change, Shareholder change, Articles of association amended, Change in Section 2 (management and representation), Primary PKD code change, Secondary PKD code change, Change in Section 6 (liquidation, bankruptcy or dissolution)
WA.XIII NS-REJ.KRS/63675/16/132
Competing companies or those operating in the same market segment as Cloud FLEX (in Warszawa, industry: Research and development).
WARSZAWA· Research and development
Revenue 2024: 2.9 B PLN
WARSZAWA· Research and development
Revenue 2024: 796.1 M PLN
WARSZAWA· Research and development
Revenue 2023: 609.6 M PLN
WARSZAWA· Research and development
Revenue 2024: 579.9 M PLN
WARSZAWA· Research and development
Revenue 2024: 499.5 M PLN
WARSZAWA· Research and development
Revenue 2024: 390.5 M PLN